Abstract 934
Background
A global phase III study confirmed the effect of eribulin mesylate (ERI) as third- or later-line chemotherapy on overall survival (OS) for advanced or metastatic breast cancer. Meanwhile, in Japan, ERI can be used as first- or second-line. However, limited reports can be found on time to treatment failure (TTF) and/or OS for ERI as first- or second-line therapy comparing to late-line therapy in clinical practice.
Methods
We conducted a prospective study in patients with inoperable or recurrent HER2-negative breast cancer starting in September, 2014. We enrolled a similar number of patients receiving ERI as first- or second-line therapy and those receiving ERI as third- or later-line therapy, and with follow-up planned for up to two years (ClinicalTrials.gov: NCT02371174). The data collected by November 2017 was analyzed. TTF and OS were estimated using the Kaplan–Meier method. Multivariate Cox regression was used to identify the factors influencing TTF and OS.
Results
We analyzed 634 patients. The mean age (± standard deviation) was 59.6 years (± 11.0), and 157 patients (24.8%) had triple-negative breast cancer. Of these patients, 319 received ERI as first- or second-line therapy and 315 as third- or later-line therapy. The median TTF (95% confidence interval [CI]) was 135 (121–164) and 119 (106–128) days, and the median OS (95% CI) was 555 (475–628) and 383 (342–459) days for first- or second-line- and third- or later-line therapy, respectively. A history of radiation therapy, complication of diabetes, liver metastasis, ECOG performance status, blood hemoglobin and aspartate aminotransferase levels at baseline, triple-negative breast cancer, and development of peripheral neuropathy after ERI treatment were significant factors influencing both TTF and OS.
Conclusions
Our real-world study showed patients with first- or second-line therapy of ERI have longer OS and TTF than those in third- or later-line therapy. These results suggested that patients with first- or second-line therapy of ERI have the potential for similar or more favorable outcomes from the ERI treatment compared with patients with third- or later-line therapy of ERI.
Clinical trial identification
NCT02371174, First release November 21, 2014.
Legal entity responsible for the study
Eisai Co., Ltd.
Funding
Eisai Co., Ltd.
Editorial Acknowledgement
Disclosure
M. Takahashi: Honorarium: Eisai, AstraZeneca, Pfizer. K. Inoue: Research funding (institutional): Eisai, Parexel, Puma Biotechnology, MSD, Novartis, GSK, Pfizer, Chugai Pharmaceutical, Daiichi Sankyo. Y. Sakata, H. Ikezawa, T. Matsuoka: Employee: Eisai Co. J. Tsurutani: Adviser: Eisai Co., Ltd. and Asahi Kasei Corporation; Honoraria: Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Roche Diagnostics K.K., Novartis Pharma, AstraZeneca K.K. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract